# Study of Tamibarotene in Patients With ADPKD

> **NCT06289998** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rege Nephro Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease (ADPKD)

## Interventions

- **DRUG:** Tamibarotene
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06289998
- **Lead sponsor:** Rege Nephro Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-22
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06289998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06289998, "Study of Tamibarotene in Patients With ADPKD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06289998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*